Ilaris (canakinumab)

Ilaris (canakinumab) is a prescription medicine indicated for the treatment of:

  • Periodic Fever Syndromes, including Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF);
  • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA);
  • Gout flares
  • Disease Indications : Rheumatoid Arthritis
  • Usage : Intravenous
Medicine approved by
  • European Medical Agency (EMA)
  • Food and Drug Administration (FDA)